Idiopathic Pulmonary Fibrosis: Diagnosis

Idiopathic Pulmonary Fibrosis: Diagnosis

“Ivor Kennedy, who suffers from idiopathic pulmonary fibrosis, explains how he was diagnosed and highlights the importance of access to good support and information following a diagnosis with IPF.” Learn more about Idiopathic Pulmonary Fibrosis: http://bit.ly/1QiRmr3…

Vitamin D to Decrease Pulmonary Fibrosis

In a new study, researchers demonstrated the protective effects of vitamin D in a mouse model of pulmonary fibrosis induced by the chemotherapeutic drug bleomycin. The research paper, entitled “Preventive effects of vitamin D treatment on bleomycin-induced pulmonary fibrosis,” was published in the Nature journal…

10 Things to Do While Waiting on the Transplant List

“For those out there who are waiting for an organ or tissue transplant. This video takes you through my top ten things to do while waiting on the transplant list to keep you your best self.” Read more about lung transplants: http://bit.ly/1SNRT3u   Note: Pulmonary Fibrosis News is strictly…

Reata Enrolls First Patient in Clinical Trial for ILD Associated Pulmonary Hypertension

Reata Pharmaceuticals recently announced the recruitment of the first patient with pulmonary hypertension associated with interstitial lung disease (PH-ILD) in their Phase 2 LARIAT clinical trial evaluating the efficacy, safety, and tolerability of experimental therapy bardoxolone methyl in the treatment of patients with pulmonary hypertension (PH). The recent enrollment is part of…

IPF-related Decline in Lung Function May Be Evident Within 6 Months

A new study reported that patients with newly diagnosed idiopathic pulmonary fibrosis (IPF) often experience lung function decline, which furthers disease progression. The study, titled “Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis,” was published in the journal…

IPF Patients and Doctors on Lookout for New Treatment Approaches

Spherix Global Insights, GmbH, a business intelligence and market research company based on Switzerland, recently reported a study revealing that idiopathic pulmonary fibrosis (IPF) remains a challenge in terms of treatment, especially since the majority of patients are diagnosed at already advanced disease stages. The Spherix study is entitled “…

Your PF Community

Woman laying down reading

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

View Forums